Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy

Aschele, C.; Negru, Maria Emanuela; Pastorino, Alessandro; Cavanna, Luigi; Zagonel, Vittorina; Barone-Adesi, Francesco; Blasi, Livio

doi:10.1001/jamaoncol.2020.6778

Cited by 22 publications

(27 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even when different types of cancers were correlated with COVID-19 mortality, NEN cases were not reported 16 . In one of the largest investigation of SARS-CoV-2 in patients with cancer which was the first focused specifically on patients receiving antitumor treatment, among around 60,000 cancer patients analyzed, no NEN were reported 35 .…”

Section: Discussionmentioning

confidence: 99%

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Fazio

Halfdanarson

Salvia

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

Background Specific data regarding COVID-19 in patients with neuroendocrine neoplasms (NEN) are lacking. This aim of this study is to describe the characteristics of NEN patients who tested SARS-CoV-2 positive. Material and methods This is a worldwide study collecting cases of NEN patients with a positive nasopharyngeal swab RT-PCR for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centers treating NEN patients were directly contacted by the principal investigator. Patients with NEN of any primary site, grade, and stage were included, excluding small-cell lung carcinoma and mixed adeno-neuroendocrine carcinoma. Results Among 81 centers directly contacted 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31 st , 2021, eight recruiting centers enrolled 89 patients. Median age was 64 years at the COVID-19 diagnosis. Most patients had metastatic, non-functioning, low/intermediate grade gastro-entero-pancreatic (GEP) NEN, on treatment with somatostatin analogs (SSA) and radioligand therapy (RLT). Most of them had comorbidities. Only 8% of patients had high grade NEN and 12% were receiving chemotherapy. Most patients had symptoms or signs of COVID-19, mainly fever and cough. Only 3 patients underwent sub-intensive treatment, whereas the majority received medical therapies, mostly antibiotics. In two third of cases, no changes occurred for the anti-NEN therapy. More than 80% of patients completely recovered without sequelae whereas 7.8% patients died due to COVID-19. Conclusions Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In the majority of cases they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Fazio

Halfdanarson

Salvia

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Figure 1 shows the PRISMA flow chart for the study screening and selection process in this research. Twenty-three trials including 19 retrospective studies [21] , [23] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] and 4 prospective studies [22] , [42] , [43] , [44] , enrolling 117735 study subjects ultimately met our criteria ( Figure 1 ). Six studies were performed in USA [25] , [26] , [29] , [31] , [35] , [40] , five in Italy [27] , [28] , [38] , [39] , [42] , four in Spain [27] , [36] , [37] , [43] , three in United Kingdom [22] , [33] , [34] , two in China [23] , [30] , one in France [41] , one in India [32] and one in Australia [21] .…”

Section: Resultsmentioning

confidence: 99%

Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis

Yang

Liu

Qin

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors (ICIs) treatment among cancer patients has been shown to have antiviral effects by reactivating exhausted T cells. However, they could also trigger inflammatory storm. Therefore, prior exposure to ICIs may influence the risk of SARS-CoV2 infection and subsequent mortality. Recent results from studies of ICIs treatment on incidence and mortality of COVID-19 are controversial. Materials and methods We searched databases PubMed, Embase, ISI of Knowledge, Cochrane Central Register of Controlled Trials (CENTRAL), as well as pre-print databases (MedRxiv and BioRxiv) for retrospective and prospective studies comparing ICIs versus other antitumor treatments in cancer patients in the area of COVID-19 pandemic. The primary outcome was the incidence of COVID-19. The secondary outcomes were mortality of COVID-19. Results Twenty-three studies with a total of 117735 patients were selected. Compared with other antitumor treatments, prior exposure to ICIs had not an increased risk of incidence [Odds ratio (OR), 0.84; 95% confidence interval (CI), 0.60-1.18; P=0.32] and mortality (OR, 1.22; 95% CI, 0.91-1.62; P=0.18) of COVID-19 infectioin. Our subgroup and meta-regression analyses indicated that prior exposure to ICIs may reduce the incidence of COVID-19 in metastatic cancer patients. Conclusions There was no significant difference on incidence and mortality of COVID-19 between prior exposure to ICIs with other anti-tumor treatments. ICIs may reduce infection susceptibility of COVID-19 in metastatic cancer patients.

show abstract

“…Many studies demonstrated a higher risk of infection and developing complications in people with malignancies [ 1 , 16 , 17 ], while others [ 3 , 5 ] showed a similar incidence of SARS-CoV-2 between people with tumors and healthcare operators. Focusing on Italian real-life experiences, a large study from Aschele et al [ 18 ] who analyzed 59,989 patients from 118 Medical Oncology Units all over Italy between 15 January and 4 May 2020, recorded a 0.68% infection rate among active treatment patients with 77% of them being hospitalized. Bertuzzi et al [ 19 ] reported a 1.8% COVID-19 incidence rate (17/1267); SARS-CoV-2 infected patients required hospitalization in 82% of cases (14/17) with a 29% fatality rate.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy

Cantini

Bastianelli

Lupi

et al. 2021

JCM

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2 IgM/IgG antibodies in solid cancer patients referred to the academic institution of the Marche Region, Italy, between 1 July and 26 October 2020 and to determine the accuracy of the rapid serological test. After performing 3767 GCCOV-402a rapid serological tests on a total of 949 patients, seroconversion was initially observed in 13 patients (1.4%). Ten (77% of the total positive) were IgG-positive, 1 (8%) were IgM-positive and 2 (15%) IgM-positive/IgG-positive. However, only 7 out of 13 were confirmed as positive at the reference serological test (true positives), thus seroprevalence after cross-checking was 0.7%. No false negatives were reported. The kappa value of the consistency analysis was 0.71. Due to rapid serological test high false positive rate, its role in assessing seroconversion rate is limited, and the standard serological tests should remain the gold standard. However, as rapid test negative predictive value is high, GCCOV-402a may instead be useful to monitor patient immunity over time, thus helping to assist ongoing vaccination programs.

show abstract

Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy

Cited by 22 publications

References 3 publications

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis

Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy

Contact Info

Product

Resources

About